Interstitial lung disease & IPF
Antifibrotics in IPF, progressive fibrosing ILD and SSc-ILD; refutation of immunosuppression for IPF.
- Trials
- 5
- Years
- 2012–2019
Sort
- 2019INBUILDProgressive fibrosing ILDIn 663 patients with non-IPF progressive fibrosing ILD, nintedanib slowed annual FVC decline compared with placebo.Read →
- 2019SENSCISSSc-ILDIn 576 patients with SSc-associated ILD, nintedanib slowed annual FVC decline compared with placebo.Read →
- 2014INPULSIS CoreAntifibrotic: IPFIn 1,066 patients with idiopathic pulmonary fibrosis, nintedanib 150 mg twice daily slowed annual FVC decline compared with placebo.Read →
- 2014ASCEND CoreAntifibrotic: IPFIn 555 patients with IPF (FVC 50–90% predicted), pirfenidone 2,403 mg/day reduced ≥10% FVC decline or death at 52 weeks compared with placebo.16.5% vs 31.8%Read →
- 2012PANTHER-IPF CoreImmunosuppression: IPFIn patients with idiopathic pulmonary fibrosis, prednisone + azathioprine + NAC increased mortality and hospitalisation compared with placebo.HR 12.1195% CI 2.83-51.85Read →